ESSA Pharma Inc.: IND 1Q2020. Developing small molecule drugs for the treatment of CRPC. Lead asset selectively blocks the n-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Preclincial data packet shows a favorable PK profile + exhibits significant exposure potential with a long half-life. Cash into 2023.
Based in...
North America
Disease Space
Public, USA
Market Cap
100MM - 500MM
999 West Broadway Street Suite 720
Vancouver, British Columbia BC V5Z 1K5

Top 10 Holders of ESSA Pharma Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Clarus Ventures LLC 16.25 3,373,053 23.98 13F 6/30/20
BVF Partners LP 14.48 3,005,589 21.37 Stakes 8/10/20
Soleus Capital Management LP (Investment Management) 13.70 2,844,187 20.22 Stakes 7/31/20
Soleus Capital Management LP 10.03 2,082,185 14.80 13F 6/30/20
Eventide Asset Management LLC 9.68 2,010,169 14.29 13F 6/30/20
BVF, Inc. 9.56 1,984,889 14.11 13F 6/30/20
Omega Fund Management LLC 7.21 1,497,448 10.65 13F 6/30/20
OrbiMed Advisors LLC 5.67 1,177,483 8.37 Stakes 8/6/20
RA Capital Management LLC 4.09 849,300 6.04 13F 6/30/20
Janus Capital Management LLC 1.93 401,596 2.86 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.